2 results
Approved WMOCompleted
Primary:to evaluate the effects of a moderate CYP3A4/5 inhibitor, diltiazem on the pharmacokinetics and pharmacodynamics (Thrombin and TRAP-induced platelet aggregation) of the study drug and its known metabolitessecundary:to evaluate the effects of…
Approved WMOCompleted
The primary objective is to measure the availability of the PDE10A enzyme in Huntington*s Disease (HD)gene expansion carriers (HDGECs) by estimating and comparing the distribution volume (VT) of the radioligand [18F]MNI-659 in the striatum (caudate…